"Phase I/IIa Trial of BP-GMAX-CD1 Vaccine Therapy plus Activating Agent AP1903 for Men with Advanced Androgen Independent Prostate Cancer"

This is a standard dose escalation Phase I study, with primary and secondary endpoints of safety, maximum tolerated dose (MTD), magnitude of antigen-specific immune response compared to pre-therapy, and preliminary efficacy (PSA, CTC, clinical response). Participants will receive six doses of vaccine, either every week or every other week, and those who remain free from disease progression at the end of this acute phase of the study will receive booster vaccinations every 8 weeks for up to one year.

The clinical trial is being conducted at the Center for Clinical and Translational Sciences, UT Health Science Center-Houston, and the Center of Innovation and Research, Memorial Hermann Hospital - TMC, Houston. An IND for this trial is in effect, as are all required institutional approvals. This clinical trial, sponsored by Bellicum Pharmaceuticals, is currently enrolling patients. 

Interested patients should visit this www.clinicaltrials.gov link.